<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941083</url>
  </required_header>
  <id_info>
    <org_study_id>HC0509</org_study_id>
    <nct_id>NCT00941083</nct_id>
  </id_info>
  <brief_title>Simplification From Protease Inhibitors to Raltegravir</brief_title>
  <acronym>ODIS</acronym>
  <official_title>Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Carlos III, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Carlos III, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A switch from protease inhibitors (PIs) to raltegravir (RAL) will be effective virologically
      and immunologically. Moreover, it will be associated with significant improvements in the
      lipid profile in HIV patients with undetectable viremia on PIs. In this setting, RAL once a
      day (QD) will perform as well as RAL twice a day (BID).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with plasma HIV-RNA &lt; 50 copies/ml at week 24 in each arm (RAL QD, RAL BID, RAL BID to QD)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 gains, lipid profile, adverse events,</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug resistance mutations</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir through plasma levels and correlation with virological failure</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>RAL QD 800 mg/24 hs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAL BID 400 mg/12 hs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RAL BID to QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir (Use RAL as a simplification strategy)</intervention_name>
    <description>RAL QD: RAL 800 mg/24 hs</description>
    <arm_group_label>RAL QD 800 mg/24 hs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir (Use RAL as a simplification strategy)</intervention_name>
    <description>RAL BID 400 mg/12 hs</description>
    <arm_group_label>RAL BID 400 mg/12 hs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir (Use RAL as a simplification strategy)</intervention_name>
    <description>RAL BID to QD</description>
    <arm_group_label>RAL BID to QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV1 sero-positive using standard diagnostic criteria

          -  Plasma viral HIV-RNA below 50 copies/ml within 180 days prior to randomization

          -  On therapy with protease inhibitors both ritonavir-boosted or un-boosted for at least
             6 months prior to study entry

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Prior use of Integrase inhibitors

          -  Alcohol or substance abuse if according to the investigator opinion would interfere
             with compliance

          -  UIse of investigational medications within 30 days before study entry or during the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Soriano, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Carlos III</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Soriano, PhD</last_name>
      <phone>+34914532536</phone>
      <email>vsoriano@dragonet.es</email>
    </contact>
    <investigator>
      <last_name>Vicente Soriano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hospital Carlos III</name_title>
    <organization>Vicente Soriano</organization>
  </responsible_party>
  <keyword>Simplification from protease inhibitors to raltegravir</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>HIV-1 Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

